Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Beneficial Ownership Report · SCHEDULE 13G

Inovio Pharmaceuticals, Inc.

INONASDAQEQUITYCurrent

Beneficial Ownership Report

Filed Nov 16, 2026Accepted Nov 16, 2026, 4:59 PM ESTFiling CIK 1232621Accession 0001214659-26-014444
Share

Structured filing — SCHEDULE 13G

primary_doc.xml

Open full document ↗

Subject company

Company
Inovio Pharmaceuticals Inc.
Company CIK
0001055726
Street
660 West Germantown Pike
Street (continued)
Suite 110
City
Plymouth Meeting
State / country code
PA
Postal code
19462

Statement details

Security class
Common Stock, par value $0.001 per share
Event date
11/06/2026
Rule designation
Rule 13d-1(c)

Reporting person 1

Name
TANG CAPITAL MANAGEMENT, LLC
Citizenship / organization
DE
Reporting person type
OO
Aggregate amount owned
17,978,200.00
Percent of class
9.99
Sole voting power
0.00
Shared voting power
17,978,200.00
Sole dispositive power
0.00
Shared dispositive power
17,978,200.00
Aggregate excludes certain shares
N
Comments
Tang Capital Management, LLC ("TCM") beneficially owns 17,978,200 shares of the Issuer's Common Stock, which consists of: (i) 17,659,259 shares of the Issuer's Common Stock and (ii) 318,941 shares currently issuable upon exercise of pre-funded warrants (the "Warrants," as defined in the Issuer's Registration Statement filed on Form 424(b)(5) with the Securities and Exchange Commission on November 6, 2026). TCM beneficially owns 10,150,264 of the Issuer's Warrants, which are each exercisable for one share of the Issuer's Common Stock. The percentages used herein are based on 179,961,968 shares of Common Stock outstanding which is comprised of: (i) 179,643,027 shares of Common Stock outstanding as of November 6, 2026 as set forth in the Issuer's Prospectus filed on Form 424(b)(5) that was filed with the Securities and Exchange Commission on November 6, 2026, and (ii) 318,941 shares currently issuable upon exercise of Warrants. TCM shares voting and dispositive power over such shares with Tang Capital Partners, LP ("TCP"), Tang Capital Partners International, LP ("TCPI"), Tang Capital Partners III, Inc. ("TCP III"), Tang Capital Partners IV, Inc. ("TCP IV") and Kevin Tang.

Reporting person 2

Name
KEVIN TANG
Citizenship / organization
X1
Reporting person type
IN
Aggregate amount owned
17,978,200.00
Percent of class
9.99
Sole voting power
0.00
Shared voting power
17,978,200.00
Sole dispositive power
0.00
Shared dispositive power
17,978,200.00
Aggregate excludes certain shares
N
Comments
Kevin Tang beneficially owns 17,978,200 shares of the Issuer's Common Stock, which consists of: (i) 17,659,259 shares of the Issuer's Common Stock and (ii) 318,941 shares currently issuable upon exercise of Warrants. Kevin Tang beneficially owns 10,150,264 of the Issuer's Warrants, which are each exercisable for one share of the Issuer's Common Stock. Kevin Tang shares voting and dispositive power over such shares with TCP, TCPI, TCP III, TCP IV, and TCM.

Reporting person 3

Name
TANG CAPITAL PARTNERS, LP
Citizenship / organization
DE
Reporting person type
PN
Aggregate amount owned
4,008,311.00
Percent of class
2.23
Sole voting power
0.00
Shared voting power
4,008,311.00
Sole dispositive power
0.00
Shared dispositive power
4,008,311.00
Aggregate excludes certain shares
N
Comments
TCP beneficially owns 4,008,311 shares of the Issuer's Common Stock, which consists of: (i) 3,937,202 shares of the Issuer's Common Stock and (ii) 71,109 shares currently issuable upon exercise of Warrants. TCP beneficially owns 2,263,042 of the Issuer's Warrants, which are each exercisable for one share of the Issuer's Common Stock. TCP may not exercise any portion of the Warrants for shares of Common Stock if, as a result of the exercise, TCP, together with its affiliates and any other person or entity acting as a group, would own more than 9.99% of the Issuer's outstanding shares of Common Stock after exercise. However, TCP may increase such percentage to any other percentage, not in excess of 19.99% (to the extent such limit is required under applicable Nasdaq rules), by providing written notice to the Issuer, provided that any increase in such percentage shall not be effective until 61 days after notice is provided to the Issuer. The foregoing limitations remain in effect with respect to the Warrants, and, accordingly, only 71,109 shares are currently issuable upon exercise of the Warrants. TCP shares voting and dispositive power over such shares with TCM and Kevin Tang.

Reporting person 4

Name
TANG CAPITAL PARTNERS INTERNATIONAL, LP
Citizenship / organization
DE
Reporting person type
PN
Aggregate amount owned
5,953,267.00
Percent of class
3.30
Sole voting power
0.00
Shared voting power
5,953,267.00
Sole dispositive power
0.00
Shared dispositive power
5,953,267.00
Aggregate excludes certain shares
N
Comments
TCPI beneficially owns 5,953,267 shares of the Issuer's Common Stock, which consists of: (i) 5,847,653 shares of the Issuer's Common Stock and (ii) 105,614 shares currently issuable upon exercise of Warrants. TCPI beneficially owns 3,361,138 of the Issuer's Warrants, which are each exercisable for one share of the Issuer's Common Stock. Based on the ownership limitations described above, only 105,614 shares are currently issuable upon exercise of the Warrants. TCPI shares voting and dispositive power over such shares with TCM and Kevin Tang.

Reporting person 5

Name
TANG CAPITAL PARTNERS III, INC
Citizenship / organization
NV
Reporting person type
CO
Aggregate amount owned
4,008,311.00
Percent of class
2.23
Sole voting power
0.00
Shared voting power
4,008,311.00
Sole dispositive power
0.00
Shared dispositive power
4,008,311.00
Aggregate excludes certain shares
N
Comments
TCP III beneficially owns 4,008,311 shares of the Issuer's Common Stock, which consists of: (i) 3,937,202 shares of the Issuer's Common Stock and (ii) 71,109 shares currently issuable upon exercise of Warrants. TCP III beneficially owns 2,263,042 of the Issuer's Warrants, which are each exercisable for one share of the Issuer's Common Stock. Based on the ownership limitations described above, only 71,109 shares are currently issuable upon exercise of the Warrants. TCP III shares voting and dispositive power over such shares with TCM and Kevin Tang.

Reporting person 6

Name
TANG CAPITAL PARTNERS IV, INC
Citizenship / organization
NV
Reporting person type
CO
Aggregate amount owned
4,008,311.00
Percent of class
2.23
Sole voting power
0.00
Shared voting power
4,008,311.00
Sole dispositive power
0.00
Shared dispositive power
4,008,311.00
Aggregate excludes certain shares
N
Comments
TCP IV beneficially owns 4,008,311 shares of the Issuer's Common Stock, which consists of: (i) 3,937,202 shares of the Issuer's Common Stock and (ii) 71,109 shares currently issuable upon exercise of Warrants. TCP IV beneficially owns 2,263,042 of the Issuer's Warrants, which are each exercisable for one share of the Issuer's Common Stock. Based on the ownership limitations described above, only 71,109 shares are currently issuable upon exercise of the Warrants. TCP IV shares voting and dispositive power over such shares with TCM and Kevin Tang.

Item 1

Issuer

Inovio Pharmaceuticals Inc.

Principal executive office address

660 West Germantown Pike, Suite 110, Plymouth Meeting, PA, 19462

Item 2

Citizenship

TCM is a Delaware limited liability company. Mr. Tang is a United States citizen. TCP and TCPI are Delaware limited partnerships. TCP III and TCP IV are Nevada corporations that are indirectly wholly owned by TCP.

Filing person

This Statement on Schedule 13G (this "Statement") is filed by TCM, the general partner of TCP and TCPI; Kevin Tang, the manager of TCM and Chief Executive Officer of TCP III and TCP IV; TCP; TCPI; TCP III; and TCP IV.

Principal business or residence address

The address of TCM, Kevin Tang, TCP and TCPI is 4747 Executive Drive, Suite 210, San Diego, CA 92121. The address of TCP III and TCP IV is 400 S. 4th Street, 3rd Floor, Las Vegas, NV 89101.

Item 3

Not applicable indication

Y

Item 4

Percent of class

9.99

Amount beneficially owned

17,978,200

Sole voting power

0 shares

Shared voting power

17,978,200 shares

Sole dispositive power

0 shares

Shared dispositive power

17,978,200 shares

Item 5

Not applicable indication

Y

Item 6

Not applicable indication

Y

Item 7

Not applicable indication

Y

Item 8

Not applicable indication

Y

Item 9

Not applicable indication

Y

Item 10

Not applicable indication

N

Certifications

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

Exhibits

Exhibit 99.1

Signature 1

Reporting person
TANG CAPITAL MANAGEMENT, LLC
Signed
/s/ Kevin Tang
Title
Manager
Date
11/16/2026

Signature 2

Reporting person
KEVIN TANG
Signed
/s/ Kevin Tang
Title
Self
Date
11/16/2026

Signature 3

Reporting person
TANG CAPITAL PARTNERS, LP
Signed
/s/ Kevin Tang
Title
Manager, Tang Capital Management, LLC, General Partner
Date
11/16/2026

Signature 4

Reporting person
TANG CAPITAL PARTNERS INTERNATIONAL, LP
Signed
/s/ Kevin Tang
Title
Manager, Tang Capital Management, LLC, General Partner
Date
11/16/2026

Signature 5

Reporting person
TANG CAPITAL PARTNERS III, INC
Signed
/s/ Kevin Tang
Title
Chief Executive Officer
Date
11/16/2026

Signature 6

Reporting person
TANG CAPITAL PARTNERS IV, INC
Signed
/s/ Kevin Tang
Title
Chief Executive Officer
Date
11/16/2026

Filed exhibits

Company context

INOVIO’s DNA medicines platform has two innovative components: precisely designed DNA plasmids, delivered by INOVIO’s proprietary medical device, CELLECTRA. INOVIO uses proprietary technology to design its DNA plasmids, which are small circular DNA molecules that enable the body’s cells to produce specific proteins to target and fight disease. INOVIO’s proprietary CELLECTRA delivery devices are designed to optimally deliver its DNA medicines to the body’s cells without requiring chemical adjuvants or lipid nanoparticles and without the risk of the anti-vector response historically seen with viral vector platforms.

Current securities

Recent company filings

  1. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsNov 17, 2026
  2. SCHEDULE 13G/A - filed by HIGHBRIDGE CAPITAL MANAGEMENT LLC regarding INOVIO PHARMACEUTICALS, INC.Nov 16, 2026
  3. Results of Operations and Financial ConditionNov 10, 2026
  4. 10-Q filingNov 10, 2026
  5. Entry into a Material Definitive Agreement · Regulation FD Disclosure · Other EventsNov 9, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.